Esposito, The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes
Abrahmsen 2023)
GLP-1 Clinical Trials Show Promising Reduction in Body Weight The most cited GLP-1 study is the STEP 1 trial , which evaluated semaglutide, the active ingredient in Wegovy, in non-diabetic adults with obesity
All three are dominated by gastrointestinal effects nausea, diarrhea, constipation, and vomiting usually strongest during dose increases
Clinical Evidence for PT-141 in Men Research on bremelanotide for male sexual dysfunction spans over 15 years, including clinical trials in men with ED and more recent real-world clinical experience
Why Kellys doctor recommended weight loss When youre prediabetic, even modest weight loss can have dramatic effects on blood sugar